What’s New


AACR: Isarna will present data concerning the anti-tumor activity of ISTH0047, a potent and selective TGF-β2 antisense oligonucleotide, in a breast cancer mouse model at the 2016 AACR (American Association of Cancer Research) Annual Meeting April 16-20 in New Orleans, Louisiana (US). Meet us at >>

ARVO: Preliminary results concerning the safety and tolerability of Isarna's ISTH0036, a potent and selective antisense oligonucleotide targeting TGF-β2, in patients with glaucoma will be presented during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 1-5 in Seattle, Washington. Meet us at >>